Tülay Köken

Tülay Köken

Auto-generated profile, based on publicly available information

Tülay Köken

AFYONKARAHISAR HEALTH SCIENCES UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES, DEPARTMENT OF BIOCHEMISTRY

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2021 in Archives of Rheumatology
Verified
Journal Article
Open access
EBErsin Bestaş
Ersin Bestaş
ÜDÜmit Dündar
Ümit Dündar
TKTülay Köken
Tülay Köken
HKHalit Buğra Koca
Halit Buğra Koca
HYHilal Yeşil
Hilal Yeşil
Objectives: This study aims to compare the effects of balneotherapy, water-based exercise (WBE), and land-based exercise (LBE) on disease activity, symptoms, sleep quality, quality of life, and serum sclerostin level (SSL) in patients with ankylosing spondylitis (AS). Patients and methods: Between January 2019 and January 2020, a total of 60 patients (35 males, 25 females; mean age: 40.9±11.2 years; range, 18 to 55 years) who were diagnosed with AS were randomly divided into the balneotherapy (n=20), WBE (n=20), and LBE (n=20) groups (20 sessions of treatment in groups of five to six patients). The patients were evaluated before treatment and at 4 and 12 weeks using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Ankylosing Spondylitis Disease Activity Score-C-reactive protein (ASDAS-CRP), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), Ankylosing Spondylitis Quality of Life (ASQoL) Scale, Fatigue Severity Scale (FSS), and Pittsburg Sleep Quality Index (PSQI), and SSL were measured. Results: Statistically significant improvements in the BASDAI, BASFI, MASES, BASMI, ASQoL, FSS, and ASDAS-CRP scores were observed in all groups at 4 and 12 weeks of follow-up (p0.05). Conclusion: Balneotherapy, WBE, and LBE are effective in the treatment of AS, and the beneficial effects may last for at least 12 weeks.

6 September 2017 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
SASema Akgün
Sema Akgün
TKTülay Köken
Tülay Köken
AKAhmet Kahraman
Ahmet Kahraman
An increased risk for metabolic syndrome (MS) has been described for people with psychotic and mood disorders. The aim of this study was to determine the influence of valproic acid (VPA) treatment on adiponectin, leptin levels and oxidative stress in bipolar disorder (BD). Forty patients with BD receiving VPA monotherapy and 20 healthy control subjects were included in this study. BD patients were divided into two groups with and without MS as group 1 and group 2, respectively. Twenty BD patients diagnosed according to the Diagnostic and Statistical Manual for Mental Disorders (DSM IV) were assessed for MS according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III) criteria. Adiponectin, leptin, protein carbonyls, sulfhydryl (–SH) and malondialdehyde (MDA) levels were measured in 40 BD patients and 20 control subjects. Serum adiponectin levels were significantly lower in group 1 patients than in group 2 and control subjects (p<.001). Serum leptin levels were significantly higher in group 1 patients than in group 2 and control subjects (p<.001). Serum –SH levels were significantly lower in group 2 patients than in group 1 (p<.001) and control subjects (p<.05). Serum carbonyl levels were significantly higher in group 1 and group 2 patients than in control subjects (p<.001). Serum MDA levels were significantly higher in group 1 patients than in group 2 and control subjects (p<.001). These results provide further evidence that VPA treatment for patients with BD contributed to the metabolic disturbances, such as the decreased serum adiponectin and –SH levels, as well as the increased serum leptin, MDA and carbonyl levels.

31 March 2023 in Eskisehir Medical Journal, Eskisehir City Hospital
Verified
Journal Article
Open access
PDF file
ÇÖÇiğdem Özdemir
Çiğdem Özdemir
FYFiliz Yavaşoğlu
Filiz Yavaşoğlu
YŞYiğit Şenol
Yiğit Şenol
MŞMerve Şahi̇n
Merve Şahi̇n
TKTülay Köken
Tülay Köken
Introduction: The diagnosis of chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), which also includes atypical forms, can be very difficult. The aim of this study is to compare immunohistochemical (IHC) and flow cytometric (FC) immunophenotyping methods in the CLL/SLL, the most common mature B-cell leukemia/lymphoma of adults, in bone marrow biopsy. In these two methods, it is to determine the minimum panels that can differentiate CLL/SLL from other mature B-cell leukemia/lymphomas. Material and Method: The study included 68 adult patients diagnosed with mature B cell leukemia/lymphoma. Final diagnoses were made on the basis of peripheral smear, bone marrow aspirate, bone marrow biopsy, IHC and FC analysis, clinical and genetic studies. Cell counts, final diagnosis and immunophenotyping were compared with both methods. Cytogenic findings were evaluated. The sensitivity, specificity, positive and negative predictive values of IHC and FC results for CLL/SLL were calculated. Results: CLL/SLL was diagnosed in 64.7% of the cases and non- CLL/SLL in 35.29% of the cases. The median age was 66.50 years, 69.18% male and 30.82% female. The diagnosis compatibility in FC and IHC was found to be highest in hairy cell leukemia/lymphoma with 100%, and in CLL/SLL with 90%. In other lymphomas, a definitive diagnosis could only be made with biopsy. Immunophenotyping made with CD23+CD43+CD5+LEF-1 in the bone marrow biopsy showed a sensitivity of 95.45% (range, 84.53-99.44%) and a specificity of 100.00% (range, 85.75-100.00%) for CLL/SLL. Immunophenotyping made with CD23+CD43+CD5+CD200+ in FC showed a sensitivity of 100.00% (range, 91.96-100.00%) and a specificity of 82.61% (range, 61.22-95.05%) for CLL/SLL. Conclusion: This was the most extensive study to have compared immunophenotyping in IHC and FC in bone marrow biopsies of mature B cell leukemia/lymphoma. The addition of LEF-1 to the CD23(+), CD43(+), CD5(+) panel in IHC and the addition of CD200 to the same panel in FC will be extremely helpful in the differential diagnosis of typical/atypical CLL/SLL from mature B cell leukemia/lymphoma.

18 July 2024 in Kocatepe Tıp Dergisi
Verified
Journal Article
Open access
PDF file
HKHalit Buğra Koca
Halit Buğra Koca
TKTülay Köken
Tülay Köken
TATülay Akan
Tülay Akan
AMAÇ: Bu çalışmada, prostat kanseri hücre hattı LNCaP hücrelerinde, apium graveolens (kereviz) bitkisinin etanolik ekstraktlarının hücre canlılığı ve apoptoziste rol alan kaspazlar ve apoptoz proteaz aktivasyon faktörü-1 (Apaf-1) üzerine indükleyici/baskılayıcı olarak anti-kanser etkisinin araştırılması amaçlandı. GEREÇ VE YÖNTEM: Çalışmamızda LNCaP hücre hattı kullanıldı. LNCaP hücreleri; 0, 1500, 2000, 2500 μg/mL arasında değişen ve artan konsantrasyonlarda apium graveolens'in etanolik ekstraktları ile muamele edilen 4 gruba ayrıldı. Belirtilen ekstrakt konsantrasyonları LNCaP hücrelerine 24 ve 48 saat ayrı ayrı uygulandı. Uygulama bitiminde hazırlanan hücre lizatından ELISA yöntemiyle; Kaspaz-3, -8, -9 ve Apaf-1 ölçümü yapıldı. Sonuçlar canlı hücre sayılarıyla oranlanarak ng/ml olarak verildi. BULGULAR: LNCaP prostat kanser hücrelerinin apium graveolens ekstraktları ile 24 ve 48 saatliğine muamelesi kaspaz-3 ve kaspaz-9 düzeylerinde anlamlı bir farklılığa neden olmadı. Bununla birlikte; 24 ve 48 saatlik uygulamada, 2000 ve 2500 μg/ml ekstrakt konsantrasyonlarında kaspaz-8 değerleri kontrol gruplarına göre ve 2500 μg/ml ekstrakt konsantrasyonunda ise Apaf-1 düzeyi kontrol gruplarına göre doza ve zamana bağımlı olarak istatistiksel bakımdan anlamlı artış gösterdi. SONUÇ: Bu çalışmanın sonuçları, apium graveolens bitkisinin etanolik ekstraktlarının uygulandığı LNCaP prostat kanser hücre hattında kaspaz-8 ve Apaf-1 düzeylerini artırarak antikanser ve apoptotik özelliğe sahip olduğunu göstermektedir. Bulgularımızı desteklemek için daha ileri in-vitro ve in-vivo çalışmalara ihtiyaç vardır.

22 July 2024 in Health Sciences Quarterly
Verified
Journal Article
Open access
PDF file
SOSeyma Oncu
Seyma Oncu
HKHalit Buğra Koca
Halit Buğra Koca
TKTülay Köken
Tülay Köken
TATülay Akan
Tülay Akan
Acorus calamus is a plant that is widely used in Far Eastern and Asian countries and has anti-inflammatory, antioxidant, anti microbial, and anti-cancer effects. Prostate cancer is a sort of cancer that is frequently diagnosed and has a high mortality rate in men. Only a limited number of studies are available showing the effects of Acorus calamus on prostate cancer. To assess the effects of Acorus calamus extract on caspase and anti-apoptotic and proapoptotic markers that play a role in the apoptotic process of LNCaP cells in prostate cancer by conducting an in vitro study. LNCaP cells were incubated for 24 and 48 hours and treated with different concentrations of an ethanolic extract of Acorus calamus ranging from 250 to 700 µg/ml. Caspase-3, -8, and -9, Bcl-2, Bax, APAF-1, Bcl-XL, and p53 levels were measured using the ELISA method. Quantitative gene expression analyzes of Bcl-2 and Bax were performed using real-time reverse transcription–polymerase chain reaction. The Mann-Whitney U and Tukey tests were used to analyse differences between groups. p<0.05 was considered statistically significant. Caspase-3 and -8 and APAF-1 levels were found to be significantly higher in the 48th-hour application of 700 µg/ml of Acorus calamus extract than in the control group (p<0.05, p<0.001, and p<0.001, respectively). Bcl-2 was significantly lower and Bax/Bcl-2 expression ratio was significantly higher at all doses for 24 and 48 hours compared to the control group (p<0.001 for all). Although, caspase-9, Bcl-XL, and p53 were higher in experimental groups than controls, no significant difference was found. This study supported the time- and dose-dependent anti-cancer effects of Acorus calamus on LNCaP cells of the prostate cancer type. Further preclinical and clinical studies are requisite to support our findings.

5 September 2025 in Turkish Society of Clinical Biochemistry
Verified
Journal Article
Closed access
ÖFÖzge Fenercioğlu
Özge Fenercioğlu
MŞMerve Şimşek
Merve Şimşek
PBPınar Baraz
Pınar Baraz
FBFurkan Berk Bilgiç
Furkan Berk Bilgiç
EŞEnes Bera Şahin
Enes Bera Şahin
ZBZehra Bincan
Zehra Bincan
Amaç: Sağlıklı bir gebelik için tiroid bozukluklarının teşhis ve tedavisi oldukça önemlidir. Gebelikte oluşan fizyolojik değişiklikler tiroid bezinin çalışmasını ve tiroid fonksiyon testlerini etkiler. Bu çalışmanın amacı, gebelerde tiroid stimülan hormon (TSH), serbest tiroksin (sT4) ve serbest triiyodotironin (sT3) testlerinin referans aralıklarını belirlemek ve kullandığımız referans aralıklarla karşılaştırmaktır. Gereç ve Yöntem: Laboratuvarımızda Ocak 2022 – Aralık 2024 tarihleri arasında, tiroid hormon testleri çalışılmış, 483 sağlıklı gebe çalışmaya dahil edildi. Her üç trimesterde herhangi bir risk faktörü ve antitiroperoksidaz pozitifliği olmayan sağlıklı gebeler çalışmaya alındı. TSH, sT4 ve sT3 analizleri laboratuvarımızda elektrokemiluminesans yöntem kullanılarak ölçüldü. Referans aralıkları, Klinik ve Laboratuvar Standartları Enstitüsü kurallarına uygun olarak hesaplandı. Bulgular: Toplamda, 221’i birinci trimesterde, 130’u ikinci trimesterde ve 132’si üçüncü trimesterde olmak üzere 483 sağlıklı gebe çalışmaya alındı. İlk trimester için referans aralıklar TSH (0,1-3,9 mIU/L), sT4 (0,9-1,5 ng/L) ve sT3 (2,6-4 ); ikinci trimester için TSH (0,5-3,3 mIU/L), sT4 (0,7-1,3 ng/L) ve sT3 (2,2-3,7 ng/L); üçüncü trimester için TSH (0,5-4 mIU/L), sT4 (0,7-1,3 ng/L) ve sT3 (2,3-3,5 ng/L) olarak hesaplandı. Sonuç: Laboratuvarda kullandığımız referans aralıklara göre TSH, sT4 ve sT3 referans üst sınırları her üç trimester için daha düşük olarak hesaplandı. Trimestere özgü uygun referans aralıkların kullanılması gebelerde tiroid fonksiyon bozukluklarının yanlış tanı veya gereksiz ya da yetersiz tedavisinin önlenmesi açısından oldukça önemlidir.